Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Graefes Arch Clin Exp Ophthalmol ; 262(6): 1745-1753, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38217767

RESUMO

PURPOSE: This study aimed to evaluate anterior flare intensity (AFI) after intravitreal injection of brolucizumab (IVBr) in patients with diabetic macular edema (DME), and to identify the factors associated with the change of AFI after IVBr. METHODS: This prospective multicenter study was conducted at five sites in Japan for patients with DME who underwent a single IVBr. AFI and central retinal thickness (CRT) were measured using a laser flare meter and spectral-domain optical coherence tomography, respectively, at weeks 0 and 6. RESULTS: Sixty-five patients (phakia, 37 eyes; pseudophakia, 28 eyes) were enrolled. Six weeks after IVBr, CRT and best-corrected visual acuity significantly improved (p < 0.0001). AFI (p = 0.0003) and age (p = 0.0054) were significantly higher in patients with pseudophakic eyes than those with phakic eyes. The AFI of the phakic eyes decreased after IVBr (p = 0.043). As the AFI before injection is higher (p = 0.0363) and the age is lower (p = 0.0016), the AFI decreases after IVBr. There was a significant positive correlation between the rates of change in CRT and AFI (p = 0.024). CONCLUSION: After IVBr, AFI decreases in phakic eyes but not in pseudophakic eyes. The age, AFI and CRT before injection and changes of CRT are involved in the change in AFI after IVBr.


Assuntos
Inibidores da Angiogênese , Anticorpos Monoclonais Humanizados , Retinopatia Diabética , Injeções Intravítreas , Edema Macular , Tomografia de Coerência Óptica , Acuidade Visual , Humanos , Edema Macular/diagnóstico , Edema Macular/tratamento farmacológico , Edema Macular/etiologia , Retinopatia Diabética/diagnóstico , Retinopatia Diabética/tratamento farmacológico , Masculino , Tomografia de Coerência Óptica/métodos , Feminino , Estudos Prospectivos , Inibidores da Angiogênese/administração & dosagem , Pessoa de Meia-Idade , Idoso , Anticorpos Monoclonais Humanizados/administração & dosagem , Anticorpos Monoclonais Humanizados/efeitos adversos , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Seguimentos , Resultado do Tratamento , Angiofluoresceinografia/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA